secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001493152-25-009922
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma appoints Christopher Cooper as interim Co-CEO to boost business activities
--------------------------------------------------------------------------------

- Christopher Cooper appointed interim Co-CEO effective March 11, 2025; focused on capital markets and business capabilities.
- Dr. Anatoly Dritschilo continues as Chairman and Co-CEO overseeing scientific and clinical trial activities.
- Consulting agreement with Cooper's entity pays $20,000/month for six months, 40 hours/week, with 30-day termination notice.
- Cooper has 27 years of management/finance experience, raised over $100M in debt and equity for prior clients.
- Company's ongoing Phase 2 trial of Ropidoxuridine for glioblastoma continues under Dritschilo's leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer